Literature DB >> 11789241

[Clinical study on treatment of incipient diabetic nephropathy by integrated traditional Chinese and Western medicine].

F Bian1, P Zhao, Z Zhang.   

Abstract

OBJECTIVE: To explore the curative effect of integrated traditional Chinese and western medicine (TCM-WM) on incipient diabetic nephropathy (DN).
METHODS: One hundred patients with incipient DN were randomly divided into two groups, the treatment group (50 cases) was treated with TCM-WM therapy, which was carried out by using Jiangtang Janshenling (JTJSL) capsule, a Chinese preparation for supplementing Qi and nourishing Yin, on the basis of controlling blood glucose with western medicine effectively. The 50 patients in the control group were treated with western medicine alone. The course of treatment was three months. Changes of symptoms, signs, and related laboratory parameters were observed before and after treatment.
RESULTS: The total effective rate in the treatment group was 90% while that in the control group was 58%, the difference between two groups was significant (P < 0.05). The related parameters including 24 hours urinary albumin excretion, blood sugar, microalbuminuria, blood and urine beta 2-microglobulin, blood lipids, and hemorrheology levels were all improved after treatment in the treatment group (P < 0.05 or P < 0.01).
CONCLUSION: The curative effect of TCM-WM was better than that of western medicine alone in treating incipient DN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11789241

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

Review 1.  Chinese herbal medicines for type 2 diabetes mellitus.

Authors:  J P Liu; M Zhang; W Y Wang; S Grimsgaard
Journal:  Cochrane Database Syst Rev       Date:  2004

2.  'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.

Authors:  Xiang Tu; Fang Liu; James B Jordan; Xue Feng Ye; Ping Fu; Fei Wang; Sen Zhong
Journal:  Trials       Date:  2013-07-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.